天津医药

天津医药 ›› 2017, Vol. 45 ›› Issue (10): 1113-1117.doi: 10.11958/20170650

• 综述 • 上一篇    下一篇

miR-205 与乳腺癌关系的研究进展

胡蕴慧，刘蕾，张瑾△   

  1. 天津医科大学肿瘤医院乳腺肿瘤三科，国家肿瘤临床医学研究中心，天津市“肿瘤防治”重点实验室，乳腺癌防治教育部重点实 验室（邮编 300060）
  • 收稿日期:2017-06-09 修回日期:2017-08-11 出版日期:2017-10-15 发布日期:2017-10-13
  • 通讯作者: 张瑾 E-mail:zhangjin@tjmuch.com
  • 作者简介:胡蕴慧（1986），女，博士，讲师，主要从事乳腺肿瘤研究
  • 基金资助:
    天津市自然科学基金;国家自然科学基金

Research progress in correlation of miR-205 and breast cancer

HU Yun-hui, LIU Lei, ZHANG Jin△   

  1. The 3rd Department of Breast Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Tianjin Breast Cancer Prevention, Treatment and Research Center, Key Laboratory of Breast Cancer Prevention and Therapy, Key Laboratory of Breast Cancer Prevention and Therapy, Tianjin 300060, China
  • Received:2017-06-09 Revised:2017-08-11 Published:2017-10-15 Online:2017-10-13

PDF (PC)

3639

摘要： 微小 RNA（miRNAs）作为一类进化保守的非编码 RNAs，通过与靶基因 mRNA 的序列互补配对抑制其翻 译或启动降解来发挥作用。越来越多的研究结果证实，miRNAs 通过发挥促癌或抑癌作用参与调控多种肿瘤的发生 与发展。其中 miR-205 在乳腺癌组织中表达普遍降低，将 miR-205 在乳腺癌细胞中过表达，则其能够通过抑制表皮 生长因子受体 3（ERBB3）、锌指 E-盒结合同源异形盒（ZEB）1、ZEB2、血管内皮生长因子 A（VEGFA）等靶基因的表 达，从而抑制癌细胞增殖、转移与侵袭能力，最终影响乳腺癌的治疗敏感性与预后。本综述重点阐述了 miR-205 在 乳腺癌中对细胞增殖、凋亡、侵袭、转移等相关基因及信号通路的调控作用与机制，miR-205 与乳腺癌患者治疗敏感 性以及患者预后的相关性，以期为乳腺癌的诊断、治疗及预后判断提供新的思路与治疗靶点。

关键词: 微 RNAs, 乳腺肿瘤, 基因疗法, 受体, 表皮生长因子, 血管内皮生长因子 A, 锌指 E-盒结合同源异形盒, miR-205

Abstract: As evolutionarily conservative small non- coding regulatory RNAs, microRNAs (miRNAs) are capable of silencing gene expression by translational repression or mRNA degradation through complementary base pairing with the mRNA of target genes. Accumulating evidence indicates that deregulation of miRNAs is often associated with human malignancies because miRNAs can function as oncogenes or tumor suppressors. Among them, miR- 205 is significantly underexpressed in breast tumors. Overexpression of miR-205 in breast cancer cells significantly inhibits cell proliferation, invasion and metastasis through repressing the expression of human epidermal growth factor receptor 3 (ERBB3), zinc finger E- box binding homeobox 1 (ZEB1), zinc finger E- box binding homeobox 2 (ZEB2), vascular endothelial growth factor A (VEGFA) and other target genes, which affects therapeutic sensitivity and prognosis of breast cancer patients. This article reviews the role and regulation of miR- 205 in breast cancer, the value of miR- 205 in clinical application and miR- 205 related research progress, which is expected to provide new strategy and therapeutic target for breast cancer diagnosis, treatment and prognosis.

Key words: microRNAs, breast neoplasms, gene therapy, receptor, epidermal growth factor, vascular endothelial growth factor A, zinc finger E - box with homologous box, miR-205